US-based obesity firm hires former Novo VP

Ed Cinca, who was behind the launches of Ozempic, Rybelsus and Wegovy at Novo Nordisk, has joined Currax Pharmaceuticals, which also has an obesity drug among its products.

After more than 18 years at Novo Nordisk, Ed Cinca left the Danish pharmaceutical company in July.

From October, he has assumed the position as senior vice president, global marketing and strategic alliance at the pharmaceutical firm Currax Pharmaceuticals, the company reports in a press release. The US-based group's lead asset is weight-loss drug Contrave, which has competition in the form of Novo Nordisk's Saxenda, now suceeded by Wegovy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs